Compare RVYL & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVYL | MYNZ |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 10.6M |
| IPO Year | N/A | 2021 |
| Metric | RVYL | MYNZ |
|---|---|---|
| Price | $6.31 | $1.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 838.4K | 588.0K |
| Earning Date | 11-14-2025 | 09-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $48,858,000.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $297.49 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 29.50 | N/A |
| 52 Week Low | $4.50 | $0.92 |
| 52 Week High | $81.55 | $8.20 |
| Indicator | RVYL | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 50.40 |
| Support Level | $5.30 | $1.15 |
| Resistance Level | $7.68 | $1.37 |
| Average True Range (ATR) | 1.03 | 0.13 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 39.58 | 22.12 |
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.